- Home
- ACRS vs SSSS Comparison
ACRS vs SSSS Comparison
Compare ACRS & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- SSSS
- Stock Information
- Founded
- ACRS 2012
- SSSS 2010
- Country
- ACRS United States
- SSSS United States
- Employees
- ACRS N/A
- SSSS N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- SSSS Finance: Consumer Services
- Sector
- ACRS Health Care
- SSSS Finance
- Exchange
- ACRS Nasdaq
- SSSS Nasdaq
- Market Cap
- ACRS 165.7M
- SSSS 138.2M
- IPO Year
- ACRS 2015
- SSSS N/A
- Fundamental
- Price
- ACRS $1.53
- SSSS $8.27
- Analyst Decision
- ACRS Strong Buy
- SSSS Strong Buy
- Analyst Count
- ACRS 9
- SSSS 4
- Target Price
- ACRS $9.25
- SSSS $9.50
- AVG Volume (30 Days)
- ACRS 1.4M
- SSSS 202.2K
- Earning Date
- ACRS 08-11-2025
- SSSS 08-11-2025
- Dividend Yield
- ACRS N/A
- SSSS 12.09%
- EPS Growth
- ACRS N/A
- SSSS N/A
- EPS
- ACRS N/A
- SSSS N/A
- Revenue
- ACRS $17,777,000.00
- SSSS $3,644,430.00
- Revenue This Year
- ACRS N/A
- SSSS $6.95
- Revenue Next Year
- ACRS $8.11
- SSSS N/A
- P/E Ratio
- ACRS N/A
- SSSS N/A
- Revenue Growth
- ACRS N/A
- SSSS N/A
- 52 Week Low
- ACRS $1.05
- SSSS $3.52
- 52 Week High
- ACRS $5.17
- SSSS $9.12
- Technical
- Relative Strength Index (RSI)
- ACRS 47.05
- SSSS 50.46
- Support Level
- ACRS $1.46
- SSSS $8.18
- Resistance Level
- ACRS $1.86
- SSSS $8.70
- Average True Range (ATR)
- ACRS 0.12
- SSSS 0.32
- MACD
- ACRS -0.02
- SSSS -0.10
- Stochastic Oscillator
- ACRS 17.54
- SSSS 14.14
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.